SCHEMBL30290791

SCHEMBL30290791

COC(=O)CCOCC(COCCC(=O)OC)(COCCC(=O)OC)NC(=O)CNC(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 3/20 0.46
MAPK1 P28482 1/20 0.45
HTT P42858 3/20 0.44
MAPT P10636 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
NPBWR1 P48145 1/20 0.44
MCHR1 Q99705 1/20 0.44
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
KDM1A O60341 1/20 0.41
RCOR1 Q9UKL0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20224802 0.93 SMN1; SMN2 (0.47) LMNASMN1; SMN2ALDH1A1MAPK1HTT
SCHEMBL20188195 0.90 HTT (0.53) LMNASMN1; SMN2ALDH1A1MAPK1HTT
SCHEMBL6564258 0.89 MEN1 (0.50) LMNASMN1; SMN2ALDH1A1MAPK1HTT
SCHEMBL18875775 0.84 ALDH1A1 (0.42) LMNASMN1; SMN2ALDH1A1MAPK1MAPT
SCHEMBL5058736 0.83 LMNA (0.51) LMNASMN1; SMN2MAPK1HTTMAPT
SCHEMBL26700511 0.81 LMNA (0.55) LMNASMN1; SMN2ALDH1A1MAPK1HTT
SCHEMBL5050709 0.81 HTT (0.57) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL11437278 0.80 ALDH1A1 (0.56) LMNASMN1; SMN2ALDH1A1MAPK1HTT
SCHEMBL11432703 0.80 ALDH1A1 (0.56) LMNASMN1; SMN2ALDH1A1MAPK1HTT
SCHEMBL5128921 0.80 LMNA (0.46) LMNASMN1; SMN2ALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125410-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS UNIV YALE (US) 2026-05-07 US disclosed
EP-4658263-A2 COMPOUNDS AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING ARTHRITIS Yale University (US) 2025-12-10 EP disclosed
WO-2024163610-A2 COMPOUNDS AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING ARTHRITIS YALE UNIVERSITY (US) 2024-08-08 WO disclosed
EP-4392430-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS Yale University (US) 2024-07-03 EP disclosed
EP-4392075-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS Yale University (US) 2024-07-03 EP disclosed
CN-117897177-A Molecular degradation agent for extracellular proteins 耶鲁大学 2024-04-16 CN disclosed
WO-2023028597-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS YALE UNIVERSITY (US) 2023-03-02 WO disclosed
WO-2023028590-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS YALE UNIVERSITY (US) 2023-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125410-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS ASGR1, COL2A1, FCGR2A LMNA 1409/4885SMN1; SMN2 4099/4885ALDH1A1 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.